Immucor's IBD Statistics Update
Hers is an update of Immucor's statistics regarding EPS, Relative
Strength, Accumulation Distribution, etc. as published in the NASDAQ
Tables of Investor's Business Daily on Monday, January 18, 1999.
Category 09/21/98 01/18/99
EPS Rank 79 83 (Up)
Relative Strength 87 53 (Down)
Group Rank N/A B
Sales/Profit Margins/ROE N/A C
Accumulation Distribution B B
Annual Earnings Growth +11% N/A
Quarter EPS Change +20% N/A
Quarter Sales Change +5% N/A
# of Funds Own N/A N/A
Legend
EPS Rank - Measures a company's earnings per share growth in the last
5 years and the stability of that growth. The %change in the last two
quarters' earnings vs. same quarters a year earlier is combined and
averaged with the 5 year record. Result is compared to all companies
in the tables and ranked on a scale of 1 to 99, with 99 the highest. A
90 rank means the company produced earnings in the top 10%. Companies
with superior earnings records rank 80 or higher.
Relative Price Strength - Measures daily each stock's relative price
change over the last 12 months compared to all other stocks in the
tables. Results are ranked 1 to 99. Stocks ranking below 70 indicate
weaker or more laggard relative performance.
Group Rank - Industry Group Relative Strength Rating compares the
stock's industry group price performance over the past 6 months to
the other 196 industry groups. A = top 20%, B = top 40%, etc. with
E = bottom 20%.
Sales/Profit Margins/ROE - Rating combines into one simple A to E
rating ('A' being best, represents the top 20% of all stocks), four
fundamental factors used by all analysts today...a company's sales
growth rate over the last 3 quarters, before- and after-tax margins,
and return on equity. Sales growth and after-tax margins are computed
using quarterly figures, and ROE and pre-tax margins are annual. All
four factors take into account acceleration (rate of increase).
Accumulation Distribution - Rating takes into account the percent
change in a stock's daily price and its volume. "A" is strongest "E"
is weakest. Accumulation-Distribution should be used with other
fundamental and technical factors to determine investment decisions.
Lets go Immucor!
Regards,
Tom |
